Intermittent Catheters Market: as Coloplast launching Luja in March 2023 as the first male catheter with more than 80 microholes CE-marked with an 816-user product evaluation across four European countries and Wellspect confirming 0% urethral trauma over a 5 to 9 year LoFric follow-up study establish the clinical innovation trajectory of hydrophilic catheters as the premium standard for clean intermittent catheterisation, Coloplast SpeediCath Compact Eve in September 2024, ConvaTec GentleCath Pro FDA approval in March 2024, and Hollister Advance Plus pediatric expansion in June 2024 confirm simultaneous access expansion across female, coated-comfort, and paediatric patient populations, so Medicare coverage of up to 200 intermittent catheters monthly for US patients sustains the home care reimbursement infrastructure that drives the North American market’s 44% global revenue share.

The global intermittent catheters market size was USD 2.62 Billion in 2025 and is expected to register a revenue CAGR of 5.4% during the forecast period. Market revenue growth is driven by factors such as the rising global prevalence of spinal cord injury, multiple sclerosis, and spina bifida-related neurogenic bladder creating a structurally growing long-term clean intermittent catheterisation patient population, clinical evidence confirming the superiority of intermittent over indwelling catheterisation for CAUTI risk reduction in long-term bladder management, and as well as product innovation expanding access across previously underserved patient populations including women, paediatric patients, and patients prioritising hydrophilic coating comfort. The first driving factor is Coloplast launching the Luja male catheter in March 2023 as the first male catheter featuring more than 80 microholes, designed to reduce the risk of urinary tract infections associated with intermittent catheterisation, CE-marked with a Coloplast data-on-file 816-user product evaluation conducted across the Netherlands, Denmark, Switzerland, and Finland, confirming triple action coating technology and complete bladder emptying at under 10 millilitres residual volume in adult male patients with urine retention from neurogenic and non-neurogenic voiding dysfunction. Hydrophilic catheters work by maintaining a slippery lubricated outer surface through water-swelled polymer coating that reduces urethral trauma and friction on insertion and withdrawal versus uncoated PVC catheters in long-term catheterisation programmes, with Wellspect product documentation at wellspect.com confirming 0% urethral trauma was identified during a 5 to 9 year follow-up study with LoFric hydrophilic catheters. The US intermittent catheters market was valued at USD 927.80 Million in 2024, with North America representing approximately 44% of global market revenue supported by Medicare coverage of up to 200 intermittent catheters monthly for eligible patients through durable medical equipment distributors. Wellspect introduced the LoFric Origo Sleeve at the European Association of Urology Nurses conference in May 2024, extending the LoFric Origo catheter range with a protective sleeve that enables a non-touch technique to minimise contamination risk during catheterisation and includes sterile salt solution for hydrophilic surface activation. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the simultaneous expansion of access across three patient population segments through distinct product innovations in 2024, which allows the intermittent catheter market to grow its addressable patient base beyond the established male neurogenic bladder population into female, paediatric, and premium-comfort market segments that were previously underserved by the available product range. Coloplast launched the SpeediCath Compact Eve catheter in September 2024, specifically designed for women with a compact form factor and integrated handling sleeve for improved discretion and ease of use in community settings, addressing the real-world adherence barrier that female intermittent catheter users face from the physical size and conspicuous appearance of standard catheter packaging. ConvaTec received FDA approval in March 2024 for its GentleCath Pro intermittent catheter with enhanced hydrophilic coating technology demonstrating reduced friction and improved patient comfort in clinical trials, extending ConvaTec’s catheter portfolio to the premium hydrophilic tier where clinical evidence supports formulary positioning at hospital and DME accounts. Hollister Incorporated expanded its Advance Plus intermittent catheter line with new pediatric sizes in June 2024, addressing the specific needs of children with neurogenic bladder conditions from spinal cord anomaly and spina bifida in a patient population requiring lifelong clean intermittent catheterisation as standard care. As a result, demand and revenue share are concentrating around the platforms with the broadest validated clinical evidence bases and the widest patient population coverage across male, female, and paediatric catheterisation categories. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the clinical innovation trajectory of hydrophilic coated intermittent catheters demonstrating measurable UTI risk reduction and zero urethral trauma outcomes that create a clinical evidence-based premium tier above standard uncoated PVC catheters in the clean intermittent catheterisation market. Clinical evidence works commercially because the Coloplast Luja’s 816-user European product evaluation across the Netherlands, Denmark, Switzerland, and Finland confirmed triple action coating technology staying bonded, staying smooth, and staying hydrated throughout catheterisation, with complete bladder emptying defined as under 10 millilitres residual volume, giving hospital urologists and continence nurse specialists a clinical evidence dossier to support formulary inclusion of Luja at premium price points versus standard catheter alternatives. Coloplast describes Luja as the first male catheter with more than 80 microholes distributed across the catheter surface to enable more uniform urine flow drainage, reducing residual urine pooling around the catheter tip that creates a bacteriuria medium, with CE-marked clinical validation as the evidence anchor for European market formulary adoption. The Wellspect LoFric platform’s Urotonic Surface Technology maintains the catheter at the same osmolality as urine, as confirmed at wellspect.com, ensuring the hydrophilic surface remains smooth during both insertion and withdrawal without friction-induced urethral trauma throughout the catheterisation procedure. The LoFric Origo Sleeve introduced at EAUN24 in May 2024 extends the LoFric Origo catheter range with a protective sleeve enabling a non-touch technique to minimise contamination risk during community self-catheterisation, with sterile salt solution included for activation. These are some of the key factors driving revenue growth of the market.

The second driver is the concurrent product launch activity expanding the intermittent catheter addressable market to three distinct patient segments simultaneously, confirming that the leading continence care companies view market broadening as the primary near-term growth strategy above premium tier penetration of the existing male catheterisation patient population. Market expansion works commercially because each new patient population segment that product innovation makes accessible adds a distinct patient cohort with its own prescribing channel, DME reimbursement pathway, and clinical protocol adoption curve above the existing male catheterisation programme at hospitals and home care DME providers. Coloplast launched SpeediCath Compact Eve in September 2024, specifically designed for women with a compact design and integrated handling sleeve for improved discretion and ease of use, with the product packaged in a small, less conspicuously medical format that addresses the primary adherence barrier for women performing community self-catheterisation in public restrooms. ConvaTec received FDA approval for GentleCath Pro with enhanced hydrophilic coating demonstrating reduced friction in clinical trials in March 2024, extending ConvaTec’s catheter portfolio to the premium hydrophilic tier with a regulatory-validated clinical claim for coating performance that had been unavailable to GentleCath at the standard product level. Hollister expanded its Advance Plus intermittent catheter line with new pediatric sizes in June 2024 for children with neurogenic bladder, addressing the specific sizing, handling, and comfort requirements of paediatric patients requiring lifelong catheterisation from spina bifida or spinal cord anomaly. These are some of the key factors driving revenue growth of the market.

Wellspect product documentation at wellspect.com confirms the LoFric Origo is the only male catheter with the same osmolality as urine, that Urotonic Surface Technology ensures the catheter remains smooth during insertion and withdrawal, and that 0% urethral trauma was identified during a 5 to 9 year follow-up study with LoFric hydrophilic catheters. Coloplast Luja CE-mark March 2023 with an 816-user product evaluation across four European markets is the first male catheter with more than 80 microholes designed to reduce UTI risk. Together these two clinical evidence anchors position hydrophilic coated catheters as the documented standard of care for long-term clean intermittent catheterisation in patients requiring lifelong bladder management.

The third driver is the institutional reimbursement and policy framework that converts clinically indicated catheterisation into commercially reimbursed per-unit demand at home care level, because Medicare coverage of up to 200 intermittent catheters monthly provides the DME reimbursement foundation that makes long-term home catheterisation programmes commercially viable for home care agencies and durable medical equipment distributors who supply, bill, and deliver catheters directly to Medicare-eligible patients with spinal cord injury, multiple sclerosis, and other qualifying neurological conditions. Reimbursement-supported demand works commercially because Medicare Part B coverage for up to 200 catheters monthly creates a predictable per-patient per-month DME supply revenue stream that allows home care catheter distributors to plan procurement, inventory, and delivery logistics against a known reimbursement rate rather than variable patient out-of-pocket willingness to pay. The US intermittent catheter market valued at USD 927.80 Million in 2024 reflects this reimbursement-anchored home care market scale. Japan’s Silver Care Act expanding elderly patient access to neurogenic bladder management provides the analogous policy driver for Asia Pacific home catheterisation demand growth. China’s volume-based procurement pilot programmes broadening patient access to intermittent catheters at public hospital settings create a second Asia Pacific policy tailwind for catheter volume expansion. These are some of the key factors driving revenue growth of the market.

However, the intermittent catheters market faces adoption constraints from high premium hydrophilic catheter cost relative to uncoated PVC alternatives limiting access in price-sensitive emerging markets and among US non-Medicare patients, patient self-catheterisation psychological and skill barriers in newly diagnosed neurogenic bladder populations, and reimbursement constraints for premium coated catheter lines among US commercial insurance payers where coverage policies do not match Medicare DME reimbursement scope. The Iran-US sanctions imposed following the United States-Iran confrontation escalation in late February 2026 affected PVC resin and medical-grade polyurethane catheter polymer supply chains through Strait of Hormuz logistics corridors, adding procurement cost uncertainty for catheter manufacturers sourcing commodity plasticiser-grade PVC compound and specialty hydrophilic coating polymer intermediates. Adherence risk from inadequate self-catheterisation technique training in home settings without continence nurse specialist support is the third constraint, as suboptimal technique increases urethral trauma and UTI risk in ways that undermine the clinical utility of premium catheter products and reduce physician confidence in initiating home catheterisation programmes for patients with limited training access. These factors substantially limit intermittent catheters market growth over the forecast period.

Based on product type, the global intermittent catheters market is segmented into hydrophilic coated catheters, uncoated standard catheters, pre-lubricated ready-to-use catheters, and paediatric catheters. Hydrophilic coated catheters account for the largest revenue share at approximately 38% of 2025 market revenue through their clinical superiority in reducing urethral trauma and UTI risk versus uncoated alternatives for long-term intermittent catheterisation patients, supported by Wellspect LoFric 0% urethral trauma in 5 to 9 year follow-up data and the Coloplast Luja 816-user European clinical evaluation. Pre-lubricated ready-to-use catheters are expected to register the fastest revenue growth rate over the forecast period at approximately 7% CAGR, driven by Coloplast SpeediCath Compact Eve September 2024, ConvaTec GentleCath Pro FDA approval March 2024, and growing patient preference for no-preparation-required catheters in work and travel settings.

Based on indication, the global intermittent catheters market is segmented into spinal cord injury, neurogenic bladder, BPH and post-surgical retention, and overactive bladder and urinary incontinence. Spinal cord injury accounts for the largest indication revenue share through the global SCI patient population requiring lifelong clean intermittent catheterisation as the standard of care for neurogenic bladder management, with SCI patients typically performing 4 to 6 catheterisations per day generating sustained per-patient daily catheter demand. Neurogenic bladder from multiple sclerosis, spina bifida, and other neurological conditions is the second-largest indication and is expected to register the fastest growth rate, driven by rising MS prevalence in Northern European and North American populations and growing spina bifida patient survival into adulthood requiring lifelong catheterisation management.

Based on regional analysis, the intermittent catheters market in North America accounted for largest revenue share in 2025 at approximately 44% of global revenue. The US market was valued at USD 927.80 Million in 2024. Medicare coverage of up to 200 intermittent catheters monthly for eligible patients through durable medical equipment distributors provides the institutional reimbursement foundation sustaining home catheterisation programme commercialisation. Coloplast, Hollister, and BD are the primary US market leaders with established Medicare DME formulary coverage and patient education support programmes. The Iran-US confrontation escalation in late February 2026 does not materially disrupt North American intermittent catheter supply chains, as primary catheter component manufacturing for Coloplast, Wellspect, and BD is concentrated in European and North American facilities outside the affected logistics corridors.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and Scandinavia represent the four largest national intermittent catheter markets within Europe. Wellspect HealthCare, headquartered in Mölndal, Sweden, holds a strong European market position through LoFric Urotonic Surface Technology with long-term urethral health data and the LoFric Origo Sleeve May 2024 non-touch technique extension. Coloplast, headquartered in Denmark, holds the leading European market position through SpeediCath and the March 2023 Luja CE-mark launch. European national health service reimbursement frameworks in the UK NHS, French Assurance Maladie, and German GKV provide access to hydrophilic intermittent catheters for neurogenic bladder patients.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period at approximately 9.8% CAGR. Japan, China, South Korea, and Australia represent the four largest national intermittent catheter markets. Japan’s Silver Care Act expanding elderly patient access to neurogenic bladder management and China’s volume-based procurement pilot programmes broadening patient access at public hospital settings confirm regulatory and policy tailwinds for Asia Pacific market expansion.

The markets in Latin America and Middle East and Africa are expected to register moderate revenue growth rates over the forecast period. Brazil and Mexico represent primary LatAm commercial markets. Growing spinal cord injury incidence from road traffic accidents in MEA countries combined with expanding specialist urology and rehabilitation medicine centres drives growing intermittent catheter demand in GCC and South African urban hospital settings.